United Therapeutics Corporation
UTHRHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, United Therapeutics Corporation focuses on Drug Manufacturers - Specialty & Generic services and products. United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United. Valued at $25.20B, UTHR is a large-cap name in its sector. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Market Cap
$25.20B
Beta
0.49
P/E (TTM)
21.04
P/E (Fwd)
19.32
EPS (TTM)
$27.92
EPS (Fwd)
$30.41
ROE
19.3%
ROA
11.6%
Cash
$2.66B
Total Debt
$0
Free CF
$557.1M
52W Change
39.5%
Annual Financials
Cash vs Debt
Where UTHR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, UTHR finished 0.55% above its 150-day moving average ($540.20) and 3.01% above its 200-day moving average ($527.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is UTHR overbought or oversold?
At the October 20, 2026 close, UTHR's RSI(14) was 66.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
United Therapeutics Corporation reports $2.66B in cash and $0 in total debt. Free cash flow comes in at $557.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 19.3% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 11.6% further supports the picture of efficient asset utilization. Revenue has grown from $1.94B (2022) to $3.18B (2025), reflecting a 64% increase over the period.
With a beta below 0.7, United Therapeutics Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing UTHR.